SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Chisa Kuga, Hirayuki Enomoto, Nobuhiro Aizawa, Tomoyuki Takashima, Naoto Ikeda, Akio Ishii, Yoshiyuki Sakai, Yoshinori Iwata, Hironori Tanaka, Masaki Saito, Hiroko Iijma, Shuhei Nishiguchi, Anti-interferon-α neutralizing antibody induced telaprevir resistance under the interferon-α plus telaprevir treatment in vitro, Biochemical and Biophysical Research Communications, 2014, 454, 3, 453

    CrossRef

  2. 2
    Pauline A. van Schouwenburg, Theo Rispens, Gerrit Jan Wolbink, Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis, Nature Reviews Rheumatology, 2013, 9, 3, 164

    CrossRef

  3. 3
    F. Matsuda, Y. Torii, H. Enomoto, C. Kuga, N. Aizawa, Y. Iwata, M. Saito, H. Imanishi, S. Shimomura, H. Nakamura, H. Tanaka, H. Iijima, H. Tsutsui, Y. Tanaka, S. Nishiguchi, Anti-interferon-α neutralizing antibody is associated with nonresponse to pegylated interferon-α plus ribavirin in chronic hepatitis C, Journal of Viral Hepatitis, 2012, 19, 10
  4. 4
    Patrick B. Deegan, Fabry disease, enzyme replacement therapy and the significance of antibody responses, Journal of Inherited Metabolic Disease, 2012, 35, 2, 227

    CrossRef

  5. 5
    Carina de Lemos Rieper, Pia Galle, Morten Bagge Hansen, Characterization and potential clinical applications of autoantibodies against cytokines, Cytokine & Growth Factor Reviews, 2009, 20, 1, 61

    CrossRef

  6. 6
    Brian P. Enright, David R. Compton, Nathaniel Collins, Thomas Davis, Barry S. McIntyre, Comparative effects of interferon alpha-2b and pegylated interferon alpha-2b on menstrual cycles and ovarian hormones in cynomolgus monkeys, Birth Defects Research Part B: Developmental and Reproductive Toxicology, 2009, 86, 1
  7. 7
    N. Kawasaki, C.-W. Lin, R. Inoue, K.-H. Khoo, N. Kawasaki, B. Y. Ma, S. Oka, M. Ishiguro, T. Sawada, H. Ishida, T. Hashimoto, T. Kawasaki, Highly fucosylated N-glycan ligands for mannan-binding protein expressed specifically on CD26 (DPPVI) isolated from a human colorectal carcinoma cell line, SW1116, Glycobiology, 2008, 19, 4, 437

    CrossRef

  8. You have free access to this content8
    Carl Jorns, Dirk Holzinger, Robert Thimme, Hans Christian Spangenberg, Manfred Weidmann, Jens Rasenack, Hubert Erich Blum, Otto Haller, Georg Kochs, Rapid and simple detection of IFN-neutralizing antibodies in chronic hepatitis C non-responsive to IFN-α, Journal of Medical Virology, 2006, 78, 1
  9. 9
    Victor E. Buckwold, William Lang, Curtis Scribner, Dennis Blanchett, Tom Alessi, Peter Langecker, Safety Pharmacology, Toxicology and Pharmacokinetic Assessment of Recombinant Human ω-Interferon Produced from CHO-SS Cells, Basic & Clinical Pharmacology & Toxicology, 2006, 99, 1
  10. 10
    H.-P. Hartung, F. Munschauer, H. Schellekens, Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference, European Journal of Neurology, 2005, 12, 8
  11. 11
    Huub Schellekens, Immunogenicity of therapeutic proteins: Clinical implications and future prospects, Clinical Therapeutics, 2002, 24, 11, 1720

    CrossRef

  12. 12
    Carolina Scagnolari, Francesca Bellomi, Ombretta Turriziani, Francesca Bagnato, Valentina Tomassini, Vito Lavolpe, Marilena Ruggieri, Fabrizio Bruschi, Giuseppe Meucci, Giordano Dicuonzo, Guido Antonelli, Neutralizing and Binding Antibodies to IFN-β: Relative Frequency in Relapsing-Remitting Multiple Sclerosis Patients Treated with Different IFN-βPreparations, Journal of Interferon & Cytokine Research, 2002, 22, 2, 207

    CrossRef

  13. 13
    C. A. Ogden, A. deCathelineau, P. R. Hoffmann, D. Bratton, B. Ghebrehiwet, V. A. Fadok, P. M. Henson, C1q and Mannose Binding Lectin Engagement of Cell Surface Calreticulin and Cd91 Initiates Macropinocytosis and Uptake of Apoptotic Cells, Journal of Experimental Medicine, 2001, 194, 6, 781

    CrossRef

  14. 14
    P. Kivisäkk, G. V. Alm, S. Fredrikson, H. Link, Neutralizing and binding anti-interferon-β (IFN-β) antibodies. A comparison between IFN-β-1a and IFN-β-1b treatment in multiple sclerosis , European Journal of Neurology, 2000, 7, 1
  15. 15
    Morton Svenson, Klaus Bendtzen, Christian Meyer, Christian Ross, Morten Bagge Hansen, Cytokine Inhibitors, 2000,

    CrossRef

  16. 16
    G.C. Viscomi, G. Antonelli, C. Bruno, L. Scapol, F. Malavasi, A. Funaro, E. Simeoni, S. Pestka, F. De Pisa, F. Dianzani, Antigenic Characterization of Recombinant, Lymphoblastoid, and Leukocyte IFN-alpha by Monoclonal Antibodies, Journal of Interferon <html_ent glyph="@amp;" ascii="&amp;"/> Cytokine Research, 1999, 19, 4, 319

    CrossRef

  17. 17
    Melisa A. Takacs, Sheila J. Jacobs, Ronald M. Bordens, Steven J. Swanson, Detection and Characterization of Antibodies to PEG-IFN-alpha2b Using Surface Plasmon Resonance, Journal of Interferon & Cytokine Research, 1999, 19, 7, 781

    CrossRef

  18. 18
    G. Antonelli, E. Simeoni, M. Currenti, F. De Pisa, V. Colizzi, M. Pistello, F. Dianzani, Interferon antibodies in patients with infectious diseases, Biotherapy, 1997, 10, 1, 7

    CrossRef

  19. 19
    Kenji Yamasaki, Jun-ichi Kira, Yoshio Koyanagi, Yuji Kawano, Naoko Miyano-Kurosaki, Minoru Nakamura, Eishi Baba, Jun Suzuki, Akifumi Yamamoto, Naoki Yamamoto, Takuro Kobayashi, Long term, high dose interferon-alpha treatment in HTLV-I-associated myelopathy/tropical spastic paraparesis: a combined clinical, virological and immunological study, Journal of the Neurological Sciences, 1997, 147, 2, 135

    CrossRef

  20. 20
    H. Schellekens, H. Niphuis, L. Buijs, P.Douw van der Krap, H.K. Hochkeppel, J.L. Heeney, The effect of recombinant human interferon α BD compared to interferon α 2b on SIV infection in rhesus macaques, Antiviral Research, 1996, 32, 1, 1

    CrossRef

  21. 21
    R Romeo, M Rumi, M Colombo, Alpha interferon treatment of chronic hepatitis C, Biomedicine & Pharmacotherapy, 1995, 49, 3, 111

    CrossRef